Baidu
map

Exp Parasitol.:两种商业性常用于降低眼压的眼药水具有抗棘阿米巴原虫活性!

2017-08-10 cuiguizhong MedSci原创

西班牙拉古纳大学热带病与公共卫生大学研究所的Sifaoui I近日在Exp Parasitol杂志上发表了一项有趣的工作,标题为"Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure."他们发现有两种常用于降低眼压的眼药水具有抗棘阿米巴

西班牙拉古纳大学热带病与公共卫生大学研究所的Sifaoui I近日在Exp Parasitol杂志上发表了一项有趣的工作,标题为"Evaluation of the anti-Acanthamoeba activity of two commercial eye drops commonly used to lower eye pressure."他们发现有两种常用于降低眼压的眼药水具有抗棘阿米巴原虫活性。

直到目前为止,对棘阿米巴角膜炎(AK)的治疗时,存在一个对大多数化学和物理药物呈高度抗性的囊肿期。因此,针对棘阿米巴角膜炎(AK)的高效治疗仍然是一个亟需解决的问题。

在他们的研究中,他们测试了两种抗青光眼滴眼剂对棘阿米巴原虫Acanthamoeba的活性。此外,基于以前的研究发现,使用β阻滞剂治疗高眼压的患者眼表上没有棘阿米巴原虫的存在,这之间可能存在联系,其中滴眼剂和β阻滞剂都含有噻吗洛尔作为活性成分。使用Alamar Blue方法,评估四种滴眼剂对棘阿米巴原虫的的除虫活性。对A. castellanii Neff囊肿期除虫效果最显着的药物,进一步研究了染色质凝集状态的变化,血浆膜的通透性,线粒体膜电位变化和经过药物处理的阿米巴原虫中的ATP的水平。

他们研究发现,即使两种滴眼剂对不同菌株Acanthamoeba的均有活性,但统计分析显示,其中一种(Timolol Sandoz)是对所有测试菌株最有效的一种,其研究结果为,在CLC16菌株中IC50为0.529%±0.206,在Acanthamoeba castellanii Neff型菌株为3.962%±0.150。 0.50%Timolol Sandoz可以通过损伤线粒体来诱导阿米巴原虫的死亡。考虑到其效果,他们认为0.50%Timoll Sandoz可用于隐形眼镜佩戴者和患有青光眼的患者的治疗中。这项工作为治疗青光眼提供了进一步的临床依据,也拓展了药物的使用领域。

原文出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (25)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2018-03-24 智慧医人
  3. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2018-06-18 gaoxiaoe
  5. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-13 zhangqingzui

    好好学习,感谢

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-11 swallow
  9. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-11 zhangqingzui

    学习了感谢

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1976065, encodeId=08fb19e606564, content=<a href='/topic/show?id=2300626294a' target=_blank style='color:#2F92EE;'>#棘阿米巴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62629, encryptionId=2300626294a, topicName=棘阿米巴)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Jan 06 23:32:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910494, encodeId=b8e41910494fe, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Mar 24 00:32:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771750, encodeId=d25f1e7175046, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Wed Nov 29 12:32:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958298, encodeId=6043195829800, content=<a href='/topic/show?id=8cab2865e4' target=_blank style='color:#2F92EE;'>#ASIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2865, encryptionId=8cab2865e4, topicName=ASIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Jun 18 05:32:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717483, encodeId=cf871e1748354, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Sun Oct 08 10:32:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793079, encodeId=ee5c1e93079ed, content=<a href='/topic/show?id=83ec1513e63' target=_blank style='color:#2F92EE;'>#RASI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15137, encryptionId=83ec1513e63, topicName=RASI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6262500044, createdName=1249862am72(暂无昵称), createdTime=Wed Oct 11 13:32:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233246, encodeId=9ae7233246b9, content=好好学习,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Sun Aug 13 21:01:24 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293990, encodeId=18571293990c7, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Fri Aug 11 15:32:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232389, encodeId=9a4123238900, content=学习了感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2cQVB0w6wKXcuEC4Enl0NTBvgHc6yoUM80A3TDia90Fo2MPicibnfm59eh7A0WoicrZXI2hde9ctxKPrlXhzNdL6oZ/0, createdBy=27371624227, createdName=zhangqingzui, createdTime=Fri Aug 11 08:02:52 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232172, encodeId=efc42321e28d, content=学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/10/737d6bda3e3be5b690accde2cfb8343b.jpg, createdBy=d1722108137, createdName=1521f80cb9m, createdTime=Thu Aug 10 14:22:50 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-10 1521f80cb9m

    学习,

    0

Baidu
map
Baidu
map
Baidu
map